Event Title
Evaluation of the appropriateness of tirofiban use in accordance to current ACC/AHA guidelines
Start Date
10-5-2016 1:00 PM
Description
Tirofiban is a tyrosine-derived non-peptide Glycoprotein IIb/IIIa (GP2b3a) inhibitor. GP2b3a inhibitor therapy during primary percutaneous coronary intervention (PCI) decreases the incidence of major adverse events as it directly affects the level of platelet inhibition. Currently tirofiban is approved for high-dose IV bolus (HDB) regimen of 25mcg/kg within 5 minutes and then 0.15mcg/kg/min infusion for up to 18 hours in patients with Non-ST-Elevation Myocardial Infarction(NSTEMI) and Unstable Angina(UA) undergoing Percutaneous Intervention(PCI). Purpose- Primary objective: To assess the appropriateness of tirofiban utilizing the 2014 AHA/ACC guideline recommendations. Secondary objectives: To identify the indication for tirofiban use; Duration of infusion post-PCI; Other antiplatelet used in conjunction; Assess complications such as bleeding or thrombocytopenia
Evaluation of the appropriateness of tirofiban use in accordance to current ACC/AHA guidelines
Tirofiban is a tyrosine-derived non-peptide Glycoprotein IIb/IIIa (GP2b3a) inhibitor. GP2b3a inhibitor therapy during primary percutaneous coronary intervention (PCI) decreases the incidence of major adverse events as it directly affects the level of platelet inhibition. Currently tirofiban is approved for high-dose IV bolus (HDB) regimen of 25mcg/kg within 5 minutes and then 0.15mcg/kg/min infusion for up to 18 hours in patients with Non-ST-Elevation Myocardial Infarction(NSTEMI) and Unstable Angina(UA) undergoing Percutaneous Intervention(PCI). Purpose- Primary objective: To assess the appropriateness of tirofiban utilizing the 2014 AHA/ACC guideline recommendations. Secondary objectives: To identify the indication for tirofiban use; Duration of infusion post-PCI; Other antiplatelet used in conjunction; Assess complications such as bleeding or thrombocytopenia